Njeri Maina, MD
Allergy & Immunology · Birmingham, ALNPI 1720213838
Payments from drug & device makers
Across 700 payments — averaging $344.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$150K
- Teva Pharmaceuticals USA, Inc.$21K
- Dermavant Sciences, Inc.$20K
- CSL Behring$12K
- Sanofi$9K
- AstraZeneca$8K
- plus $22K from 33 others
What the payments were for
- Consulting fees$3,1657%
- Speaking & faculty fees$25,40358%
- Travel & lodging$2551%
- Food & beverage$14,68034%
- Education$1890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 23 | $149,648 |
| Teva Pharmaceuticals USA, Inc. | 25 | $20,767 |
| Dermavant Sciences, Inc. | 23 | $20,422 |
| CSL Behring | 16 | $11,716 |
| Sanofi | 64 | $8,650 |
| AstraZeneca | 128 | $8,060 |
| Optinose US, Inc. | 61 | $6,678 |
| GSK | 111 | $4,957 |
| Gilead | 1 | $4,000 |
| Regeneron Healthcare Solutions, Inc. | 33 | $916 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $802 |
| Genentech USA, Inc. | 26 | $636 |
| Novartis | 19 | $518 |
| Pfizer | 28 | $506 |
| Amgen | 12 | $378 |
| Octapharma USA, Inc. | 11 | $307 |
| Biocryst US Sales Co., LLC | 13 | $297 |
| Kaleo, Inc. | 16 | $282 |
| AbbVie | 8 | $248 |
| Sanofi-aventis U.S. LLC | 2 | $177 |
| Boehringer Ingelheim | 11 | $169 |
| Grifols USA, LLC | 6 | $164 |
| Pharming Healthcare, Inc. | 4 | $101 |
| LEO Pharma Inc. | 3 | $80 |
| Lilly USA, LLC | 3 | $77 |
| Alk-abello, Inc | 4 | $75 |
| Phathom Pharmaceuticals, Inc. | 3 | $74 |
| Organon | 3 | $67 |
| Ionis Pharmaceuticals, Inc. | 2 | $62 |
| Incyte Corporation | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Blueprint Medicines Corporation | 1 | $32 |
| Genentech, Inc. | 1 | $31 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Merck | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
| Aytu Biopharma, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| USWM, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$241,087 in reported general payments places this provider in the 85th percentile of 30 allergy & immunology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 25 | $96,606 |
| Dupixent SyringeDupilumab | 13 | $48,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $38,049 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,640 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,750 |
| Arnuity ElliptaFluticasone Furoate | 20 | $5,167 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,627 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $2,514 |
| Epinephrine | 15 | $2,383 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,889 |
| Ipratropium Bromide | 50 | $1,280 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,084 |
| Azelastine Hcl | 54 | $1,019 |
| Fluticasone Propionate | 59 | $760 |
| Ventolin HfaAlbuterol Sulfate | 11 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire | $8,060 | $96,60625 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $4,957 | $52,96685 claims |
| Boehringer IngelheimSpiriva Respimat | $169 | $10,64015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 allergy & immunology providers in Alabama.
Other allergy & immunology in Birmingham
- Thomas AtkinsonBirmingham$155K
- Michael PolcariBirmingham$86K
- Miranda CurtissBirmingham$46K
- Carol SmithBirmingham$11K
- Amy CajacobBirmingham$8K
- Tracy HwangpoBirmingham$5K
- William MasseyBirmingham$3K
- Elizabeth GeorgeBirmingham$3K
- Kathleen GrisantiBirmingham$1K
- John AndersonHomewood$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.